Mesoblast keeps gaining ground
Mesoblast saw its stock climb 12%, following up on gains made yesterday. The Australia-based company had said early Monday that its rexlemestrocel-L candidate treatment for the prevention of post-implantation mucosal bleeding in end-stage chronic heart failure patients requiring a left ventricular assist device had gotten the orphan drug designation from the U.S. Food and Drug Administration. That designation will potentially provide Mesoblast with additional incentives, including market exclusivity upon approval, fee exemptions, tax credits, and other assistance. Mesoblast expects to meet with the FDA to come up with an approval pathway to accelerate release, and investors are warming up to the idea that the drugmaker could be putting itself in position to take advantage of a lucrative niche market.
- Forums
- ASX - By Stock
- MSB
- MSB Trading - 2019
MSB Trading - 2019, page-1370
-
- There are more pages in this discussion • 3,055 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.19 |
Change
-0.025(2.07%) |
Mkt cap ! $1.364B |
Open | High | Low | Value | Volume |
$1.21 | $1.21 | $1.18 | $808.7K | 678.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 111197 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 16783 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 111404 | 1.185 |
11 | 67510 | 1.180 |
12 | 137676 | 1.175 |
6 | 48214 | 1.170 |
2 | 8550 | 1.165 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 12233 | 7 |
1.195 | 33640 | 10 |
1.200 | 25041 | 16 |
1.205 | 63512 | 8 |
1.210 | 126073 | 14 |
Last trade - 11.09am 02/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
BM8
BATTERY AGE MINERALS LTD
Nigel Broomham, CEO
Nigel Broomham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online